Publicaciones en colaboración con investigadores/as de Hospital General Universitario de Alicante (14)

2014

  1. Zoledronic acid in the treatment of metastatic breast cancer

    Anti-Cancer Drugs, Vol. 25, Núm. 1, pp. 1-7

2010

  1. Adjuvant docetaxel for high-risk, node-negative breast cancer

    New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210

  2. Current controversies in the management of breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286

  3. Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))

    Clinical and Translational Oncology

2008

  1. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814

  2. Time-to-progression in breast cancer: A stratification model for clinical trials

    Breast, Vol. 17, Núm. 3, pp. 239-244

2007

  1. Current controversies in the management of early breast cancer

    Clinical and Translational Oncology, Vol. 9, Núm. 6, pp. 375-384

  2. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials

    Cancer Treatment Reviews, Vol. 33, Núm. 5, pp. 474-483

  3. Recomendaciones para la prevención, diagnóstico y tratamiento de osteonecrosis de los maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos

    Medicina Oral, Patologia Oral y Cirugia Bucal, Vol. 12, Núm. 4, pp. 279-283

  4. The use of taxanes in the neoadjuvant treatment of breast cancer: A review of randomized phase II/III trials

    Clinical Breast Cancer, Vol. 7, Núm. 10, pp. 764-774

2005

  1. Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with bone metastases (BOMET-QoL)

    Journal of Outcomes Research, Vol. 9, Núm. 15-27, pp. 15-27

2003

  1. A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer

    Clinical Breast Cancer, Vol. 4, Núm. 4, pp. 286-291

2000

  1. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer

    Clinical Cancer Research, Vol. 6, Núm. 6, pp. 2356-2362

  2. Doxorubicin and paclitaxel in advanced breast carcinoma: Importance of prior adjuvant anthracycline therapy

    Cancer, Vol. 89, Núm. 11, pp. 2169-2175